Welcome to our dedicated page for Inmune Bio news (Ticker: INMB), a resource for investors and traders seeking the latest updates and insights on Inmune Bio stock.
INmune Bio Inc. develops clinical-stage immunology and biotechnology treatments designed to target the innate immune system in disease. Company news commonly centers on three platforms: CORDStrom, a pooled allogeneic human umbilical cord-derived mesenchymal stromal/stem cell platform; XPro, a dominant-negative TNF platform intended to selectively neutralize soluble TNF; and INKmune, a cell-based medicine designed to prime natural killer cells against residual cancer.
Recurring updates include clinical and preclinical data, regulatory pathway discussions, manufacturing and collaboration agreements, conference presentations, shareholder communications, and quarterly or annual financial results. Coverage also reflects program areas such as recessive dystrophic epidermolysis bullosa, early Alzheimer’s disease, neuroinflammation, inflammatory disease and oncology.
Summary not available.
INmune Bio, Inc. (NASDAQ: INMB) announced the completion of its public offering, raising approximately $23.1 million by issuing 2,500,000 shares at $10.00 per share. The offering included 2,173,914 shares and an additional 326,086 shares sold under the underwriters' option. The proceeds are intended for general corporate purposes, specifically research and development, including clinical trials. The offering was conducted under a shelf registration statement effective since April 2020.
INmune Bio, Inc. (NASDAQ: INMB) announced pricing for its underwritten public offering of 2,173,914 shares at $10.00 each, potentially raising approximately $21.7 million before expenses. An additional 326,086 shares may be purchased by underwriters. The offering is anticipated to close by July 20, 2020. The net proceeds of around $20 million will support general corporate needs, especially research and clinical trials for their product platforms targeting immune system-related diseases.
INmune Bio, a clinical-stage biotechnology company, has announced an underwritten public offering of common stock, subject to market conditions. The offering includes a 15% over-allotment option for underwriters. Proceeds will be used for working capital, corporate purposes, and to advance the company’s product candidates. The offering will utilize an effective shelf registration statement filed with the SEC. This press release does not constitute an offer to sell or buy securities in any jurisdiction where it would be unlawful.
INmune Bio (NASDAQ: INMB) reported encouraging interim results from its Phase Ib clinical trial of XPro1595, showcasing its ability to reduce neuroinflammation in Alzheimer's patients. In comparison to a control group, patients treated with XPro1595 showed a 40.6% reduction in inflammation in the Arcuate Fasciculus and overall reductions in white matter free water, indicating potential cognitive benefits. The study aims to explore XPro1595's efficacy in targeting soluble TNF without affecting other TNF forms. The Company will discuss these findings in a KOL event scheduled for July 14, 2020.
INmune Bio, Inc. (NASDAQ: INMB) has received MHRA approval to initiate a Phase I clinical trial for INKmune, a therapy designed to activate patients' NK cells to combat high-risk Myelodysplastic Syndrome (MDS). This first-in-man trial aims to enroll 9 patients at a UK center, targeting a start in the latter half of 2020. Dr. Marion Wood emphasizes the need for better-tolerated treatment options for elderly patients unable to undergo high-dose chemotherapy. The company aims to demonstrate improved NK cell activity in patients as a novel approach to therapy.
INmune Bio has presented a study supporting the use of INB03 in combination with lapatinib for women with HER2+ breast cancer exhibiting resistance to trastuzumab. This study is crucial for the upcoming Phase II trial aimed at treating patients with CNS metastasis. The findings, shared at the New York Academy of Science, suggest that soluble TNF plays a significant role in trastuzumab resistance. INmune Bio plans to leverage this research to enhance therapeutic options for patients suffering from this aggressive cancer.
INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage biotechnology firm, will host a conference call on May 14, 2020, at 4:30 PM ET to discuss its first-quarter financial results ending March 31, 2020. The company focuses on developing treatments leveraging the innate immune system, with ongoing clinical trials for various platforms including DN-TNF for diseases such as COVID-19 and cancer, and Natural Killer Cell Priming with INKmune™. These treatments are aimed at chronic inflammation and hematologic malignancies.
INmune Bio, a clinical-stage immunology company, announced participation by CEO RJ Tesi in a COVID-19 therapeutics panel at Maxim Group’s Infectious Disease Virtual Conference on May 5, 2020. Tesi will discuss treating COVID-19's inflammatory aspects, attributing significant roles to hypertension and obesity, which increase hospitalization risks. He emphasized endothelial activation by soluble TNF as a critical factor in severe COVID-19 cases, advocating for sTNF-targeted therapies that mitigate inflammation without immunosuppression. INmune Bio's product platforms focus on therapies addressing innate immune dysfunction in diseases including cancer, Alzheimer's, and NASH, utilizing cutting-edge approaches to treatment.